Comparison of the clinicohematologic features and XCIPs in studies of patients with essential thrombocythemia
| Reference . | No. patients . | Age, y . | Platelet count, × 109/L . | Splenomegaly . | Follow-up, mo . | Vascular complications . | P . | |
|---|---|---|---|---|---|---|---|---|
| Hemorrhage (%) . | Thrombosis (%) . | |||||||
| El-Kassar et al5 (n = 33) | .330 | |||||||
| Monoclonal | 19 | 48 (16-65) | 1025 (631-2160) | NA | 42 (1-123) | NA | 6 (31.6)4-151 | — |
| Polyclonal | 14 (30.4%)4-150 | 37 (13-76) | 766 (600-1400) | NA | 54.5 (1-336) | NA | 3 (21.4)4-151 | — |
| Harrison et al6 (n = 23) | .039 | |||||||
| Monoclonal | 10 | 53 (11-64) | 722 (600-1457) | 5 | 83 (18-260) | 1 (10) | 6 (60) | — |
| Polyclonal | 13 (28.3%)4-150 | 48 (15-84) | 778 (600-1917) | 2 | 32 (6-116) | 0 (0) | 2 (15) | — |
| Chiusolo et al8 (n = 32) | .040 | |||||||
| Monoclonal | 17 | 37 (22-59) | 779 (391-1300) | NA | 24 (5-180) | NA | 7 (41.7) | — |
| Polyclonal | 15 (37.5%)4-150 | 37 (24-64) | 656 (309-1000) | NA | 36 (9-120) | NA | 1 (6.7) | — |
| Current study (n = 48) | .073 | |||||||
| Monoclonal | 33 | 50 (16-65) | 1212 (753-2400) | 8 | 46 (14-156) | 5 (15.2) | 11 (33.3) | — |
| Polyclonal | 15 (19%)4-150 | 43 (21-76) | 1176 (706-1752) | 2 | 49 (18-102) | 2 (13.3) | 1 (6.7) | — |
| Reference . | No. patients . | Age, y . | Platelet count, × 109/L . | Splenomegaly . | Follow-up, mo . | Vascular complications . | P . | |
|---|---|---|---|---|---|---|---|---|
| Hemorrhage (%) . | Thrombosis (%) . | |||||||
| El-Kassar et al5 (n = 33) | .330 | |||||||
| Monoclonal | 19 | 48 (16-65) | 1025 (631-2160) | NA | 42 (1-123) | NA | 6 (31.6)4-151 | — |
| Polyclonal | 14 (30.4%)4-150 | 37 (13-76) | 766 (600-1400) | NA | 54.5 (1-336) | NA | 3 (21.4)4-151 | — |
| Harrison et al6 (n = 23) | .039 | |||||||
| Monoclonal | 10 | 53 (11-64) | 722 (600-1457) | 5 | 83 (18-260) | 1 (10) | 6 (60) | — |
| Polyclonal | 13 (28.3%)4-150 | 48 (15-84) | 778 (600-1917) | 2 | 32 (6-116) | 0 (0) | 2 (15) | — |
| Chiusolo et al8 (n = 32) | .040 | |||||||
| Monoclonal | 17 | 37 (22-59) | 779 (391-1300) | NA | 24 (5-180) | NA | 7 (41.7) | — |
| Polyclonal | 15 (37.5%)4-150 | 37 (24-64) | 656 (309-1000) | NA | 36 (9-120) | NA | 1 (6.7) | — |
| Current study (n = 48) | .073 | |||||||
| Monoclonal | 33 | 50 (16-65) | 1212 (753-2400) | 8 | 46 (14-156) | 5 (15.2) | 11 (33.3) | — |
| Polyclonal | 15 (19%)4-150 | 43 (21-76) | 1176 (706-1752) | 2 | 49 (18-102) | 2 (13.3) | 1 (6.7) | — |
Except for number of patients, values in parentheses are ranges, preceded by medians. Each P value represents the difference in the risk for thrombosis between monoclonal and polyclonal XCIPs in each series.
NA indicates not available.
Indicates the frequency of polyclonal XCIPs in patients with informative human androgen receptor gene polymorphism.
Numbers of all vascular complications (also including hemorrhage) that occurred.